FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly pharmaceutical preparations, namely: plasters for transdermal application. Substance of invention consists in the fact that a transdermal plaster representing a matrix system and comprising a lining layer, a matrix layer and a lightproof protective coating in the following proportions is produced: 6.72 wt % of hypoxene substance, 15.11 wt % of sodium metabisulphite in propylene glycol with 0.067% of sodium metabisulphite, as well as 56.0 wt % of 95% ethanol and 22.17 wt % of PVP K30. The plaster aims at the transdermal introduction of hypoxene. A plaster area is 25 cm2.
EFFECT: offered plaster used for treating and preventing chronic diseases allows avoiding the problems related to oral administration, improves patient compliance, enables prolonged maintenance of the hypoxene concentration; it is suitable for purposes of combination therapy.
6 dwg, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
TRANSDERMAL PLASTER | 2010 |
|
RU2445123C2 |
PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ALPRAZOLAM | 2018 |
|
RU2694232C1 |
TRANSDERMAL PLASTER | 2006 |
|
RU2420269C2 |
TRANSDERMAL PLASTER FOR INTRODUCING 17-DEACETYLNORHESTIMATE SEPARATELY OR IN COMBINATION WITH ESTROGEN | 1996 |
|
RU2177311C2 |
MATRIX BASED ON ACRYLIC ADHESIVE WITH COMPLEX OF TRANSDERMAL TRANSFER ACTIVATORS FOR TRANSDERMAL THERAPEUTIC SYSTEMS | 2023 |
|
RU2812184C1 |
THERMOFUSIBLE TTS FOR APPLYING ROTIGOTIN | 2003 |
|
RU2304434C2 |
HIGHLY PURE 3,3-DIPHENYLPROPYLAMINO MONOESTERS | 2004 |
|
RU2394019C2 |
TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE | 2019 |
|
RU2798017C2 |
TRANSDERMAL ADMINISTRATION OF MEMANTINE | 2011 |
|
RU2578971C2 |
DEVICE FOR TRANSDERMAL INTRODUCTION OF ROTIGOTINE IN ORGANISM IN FORM OF BASE | 2003 |
|
RU2340339C2 |
Authors
Dates
2012-03-20—Published
2010-04-27—Filed